Novo Nordisk sees strong 2024 sales and profit growth
Shares of Denmark’s Novo Nordisk rose 3.5% to 613.30 kroner this morning, after the company reported better-than-expected net profit amid soaring demand for its Wegovy (semaglutide) obesity drugs, but forecast a slight slowdown in sales for 2025.
Novo Nordisk A/S is prepared for potential tariffs from US President Donald Trump, the Danish drugmaker’s chief executive ...
Novo Nordisk A/S has filed its Annual Report 2024 on Form 20-F for the financial year 2024 with the US Securities and ...
Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig ...
Drugmakers have poured small fortunes into the development of weight loss medicines in the past few years in attempts to lead ...
Novo Nordisk reported turnover from obesity treatments soared by 57 per cent to 65.1 billion Danish kroner last year, largely ...
Operating profit increased by 25% in Danish kroner and by 26% at constant exchange rates (CER) to DKK 128.3 billion.
The Bagsvaerd, Denmark-based company said it had net income of 91 cents per share. The results exceeded Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment ...
Novo Nordisk has a dominant position in diabetes and weight-loss drugs, strong financial growth outlook, and great potential. Click to read why NVO is a Strong Buy.
Whales with a lot of money to spend have taken a noticeably bullish stance on Novo Nordisk. If we consider the specifics of ...
In 2024, on its 100th anniversary, the Novo Nordisk Foundation reached a new milestone, awarding close to DKK 10.1 billion (€1.35 billion) to support nearly 1,800 new projects aimed at improving ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback